Immunome (IMNM) Enterprise Value (2023 - 2025)
Immunome's Enterprise Value history spans 3 years, with the latest figure at -$653.5 million for Q4 2025.
- For Q4 2025, Enterprise Value fell 200.72% year-over-year to -$653.5 million; the TTM value through Dec 2025 reached -$653.5 million, down 200.72%, while the annual FY2025 figure was -$653.5 million, 200.72% down from the prior year.
- Enterprise Value reached -$653.5 million in Q4 2025 per IMNM's latest filing, down from -$272.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$38.4 million in Q2 2023 to a low of -$653.5 million in Q4 2025.
- Average Enterprise Value over 3 years is -$239.0 million, with a median of -$254.1 million recorded in 2024.
- Peak YoY movement for Enterprise Value: plummeted 624.58% in 2024, then rose 3.7% in 2025.
- A 3-year view of Enterprise Value shows it stood at -$138.1 million in 2023, then tumbled by 57.3% to -$217.3 million in 2024, then plummeted by 200.72% to -$653.5 million in 2025.
- Per Business Quant, the three most recent readings for IMNM's Enterprise Value are -$653.5 million (Q4 2025), -$272.6 million (Q3 2025), and -$268.1 million (Q2 2025).